Yang Mingxiao, Baser Raymond E, Li Susan Q, Hou Yen-Nien, Chong Kamyar, Zhang Yi Lily, Hoque Irfan, Bao Ting, Mao Jun J
Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering, New York, NY, United States.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering, New York, NY, United States.
Front Pharmacol. 2022 May 4;13:878371. doi: 10.3389/fphar.2022.878371. eCollection 2022.
Chronic pain is common and debilitating in cancer survivors. Tibetan herbal pain-relieving plaster is used as an external analgesic to treat musculoskeletal pain in China; however, its safety and efficacy have not been evaluated via clinical trials in cancer survivors. We designed this Phase II randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov Identifier: NCT04916249) to assess the efficacy and safety of the pain-relieving plaster for temporary pain relief among cancer survivors with chronic musculoskeletal pain. Under ethical approval from the Institutional Review Board at the Memorial Sloan Kettering Cancer Center, we will enroll eligible cancer survivors who have a clinical diagnosis of moderate to severe chronic musculoskeletal pain in this study. We use a central randomization system to allocate the eligible participants to either the treatment or the control group in a 1:1 ratio, with stratification by baseline opioid use. We will instruct the participants to apply the herbal patch (Tibetree Pain-Relieving Plaster, Tibet Cheezheng Tibetan Medicine Co. Ltd., Tibet, China) or placebo patch daily at the focal area with worst pain for 14 consecutive days. Study physician, participant, outcome assessor, and biostatistician are blinded to the group allocation. The primary outcome is pain severity measured by the Brief Pain Inventory on Days 2-7. Secondary outcomes include changes in insomnia, anxiety, depression, fatigue, pressure pain threshold, pain medication use, and global impression of change. We will also monitor the adverse events throughout the study period. Statistical analysis will follow the intention-to-treat principle and linear mixed modeling will be used. With rigorous design and implementation, this randomized, placebo-controlled trial will provide the initial evidence on the efficacy and safety of the pain-relieving plaster for pain relief among cancer survivors with chronic musculoskeletal pain.
慢性疼痛在癌症幸存者中很常见且使人衰弱。藏药止痛膏在中国被用作外用镇痛药来治疗肌肉骨骼疼痛;然而,其安全性和有效性尚未在癌症幸存者中通过临床试验进行评估。我们设计了这项II期随机、双盲、安慰剂对照试验(ClinicalTrials.gov标识符:NCT04916249),以评估该止痛膏对患有慢性肌肉骨骼疼痛的癌症幸存者临时缓解疼痛的疗效和安全性。在纪念斯隆凯特琳癌症中心机构审查委员会的伦理批准下,我们将在本研究中招募临床诊断为中度至重度慢性肌肉骨骼疼痛的合格癌症幸存者。我们使用中央随机系统以1:1的比例将合格参与者分配到治疗组或对照组,并按基线阿片类药物使用情况进行分层。我们将指导参与者连续14天每天在疼痛最严重的病灶部位涂抹草药贴剂(藏医止痛膏,西藏藏芝正藏药有限公司,中国西藏)或安慰剂贴剂。研究医生、参与者、结果评估者和生物统计学家对分组情况不知情。主要结局是在第2至7天通过简明疼痛量表测量的疼痛严重程度。次要结局包括失眠、焦虑、抑郁、疲劳、压痛阈值、止痛药物使用情况的变化以及总体变化印象。我们还将在整个研究期间监测不良事件。统计分析将遵循意向性分析原则,并使用线性混合模型。通过严谨的设计和实施,这项随机、安慰剂对照试验将为该止痛膏对患有慢性肌肉骨骼疼痛的癌症幸存者缓解疼痛的疗效和安全性提供初步证据。